EA
TVTX icon

Emerald Acquisition’s Travere Therapeutics TVTX Stock Holding History

Emerald Acquisition’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$2.43M Sell
108,745
-22,191
-17% -$422K ﹤0.01% 1646
2016
Q2 		$2.33M Buy
+130,936
New +$2.12M ﹤0.01% 1758

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Emerald Acquisition's TVTX Position: Q3 2016 in Review

Emerald Acquisition reduced its Travere Therapeutics (TVTX) stake by 17% in Q3 2016, selling an estimated $422K and leaving 108,745 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1646.

Emerald Acquisition first reported a position in TVTX in Q2 2016 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold TVTX as of Q3 2016.

  • Emerald Acquisition held 108,745 shares of Travere Therapeutics worth $2.43M as of Q3 2016.
  • Emerald Acquisition sold 22,191 Travere Therapeutics shares in Q3 2016, an estimated $422K.
  • Travere Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1646 holding.
  • Emerald Acquisition first reported a position in Travere Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.